Know Cancer

forgot password

Umbilical Cord Blood Transplantation as Treatment of Adult Patients With Hematologic Disorders

Open (Enrolling)
Hematological Malignancy, Bone Marrow Failure Syndrome

Thank you

Trial Information

Umbilical Cord Blood Transplantation as Treatment of Adult Patients With Hematologic Disorders

Inclusion Criteria:

Patients must have a histologically confirmed diagnosis at The Vancouver General Hospital
or the BCCA-Vancouver.

Eligible patients will have one of the following underlying diseases:

- High risk acute lymphoblastic leukemia (ALL) in first complete remission, with high
risk being defined by the presence of t(4;11), t(9;22) or t(1;19) or patients
presenting with extreme hyperleukocytosis (WBC >100x109/L) or failure to achieve a
complete remission after standard induction therapy.

- Acute myeloid leukemia (AML) in first complete remission with high risk cytogenetics
or failure to achieve complete remission after standard induction therapy. ALL or AML
in second or subsequent remission

- Myelofibrosis with myeloid metaplasia.

- Chronic myeloid leukemia in chronic (failed interferon and/or Gleevec) or accelerated

- Myelodysplastic syndrome with IPSS risk category >Int-1

- Aplastic anemia

- Non-Hodgkin's lymphoma, chronic lymphocytic leukemia or Hodgkin's disease in relapse
or second or subsequent remission.

- Multiple Myeloma

- No active central nervous system (CNS) disease.

- No 9/10 or better HLA antigen matched related donor or VUD available.

- The patient's condition precludes waiting to search and find a VUD in the Unrelated
Donor Registries

- Acceptance of standard blood product support

- Adequate organ function as defined by current Leukemia/BMT Program of BC standards
(Appendix 10.1)

- Karnofsky performance status ≥ 80 (Appendix 10.2)

Exclusion Criteria:

- Active infection

- Pregnancy

- Significant psychiatric disorder

- Progressive disease

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the safety and efficacy of multiple cord blood transplantation in patients with hematological malignancy.

Safety Issue:


Principal Investigator

Donna Hogge

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of British Columbia - Vancouver Coastal Health Research Institute


Canada: Health Canada

Study ID:




Start Date:

May 2009

Completion Date:

December 2012

Related Keywords:

  • Hematological Malignancy
  • Bone Marrow Failure Syndrome
  • Unrelated Umbilical Cord Blood Transplant
  • Multiple cord blood
  • Neoplasms
  • Hematologic Diseases
  • Pancytopenia
  • Hematologic Neoplasms
  • Hemoglobinuria, Paroxysmal